UFPT

In the past six months, UFP Technologies reported its first-quarter 2026 financial results with net sales increasing by 4.1% and net income rising by 1.8%. Medical market sales grew by 5.9%. Despite beating adjusted EPS estimates, the stock hit a new 52-week low. Management highlighted strong momentum in its MedTech business and announced plans to increase capacity with two new facilities in the Dominican Republic. An amended supply agreement with Intuitive Surgical was also a notable development. The company acknowledged near-term headwinds, including seasonality, program phasing, softer non-medical demand, and start-up expenses. A cyber incident in February 2026 also incurred non-recurring legal expenses. Analyst ratings generally maintain a "Hold" consensus.